Novo Nordisk is facing growing challenges in the obesity treatment market, with its stock down over 50% in the past year. The decline reflects rising competition, unmet expectations for new drugs, and regulatory uncertainty. U.S. based Eli Lilly has gained ground with its drug Zepbound, which shows greater average weight loss than Novo Nordisk’s Wegovy. While Novo Nordisk argues that comparisons are misleading due to dosage differences and...